Sai LifeQ1 FY27
Sai Life Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹1,432P/E: 84.1Market Cap: ₹30.9K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- →Sai Life Sciences projects a **long-term revenue growth guidance of 15% to 20%** over a 3-to-5-year horizon.
- →The company reported a **30% annualized growth** last year, indicating strong momentum.
- →Growth is expected despite inherent business lumpiness, with a plan to **balance capacity expansion and technology investment**.
- →The CDMO business anticipates **better performance in the second half of FY27**, driven by new capacity coming online.
- →Expanded collaborations via **dedicated FTE development contracts** and integrated service models with large pharma are expected to deepen customer relationships and pipeline.
- →Strategic investments, including significant capex (~INR 1,100-1,300 crores for FY27), aim to build capabilities in peptides and other modalities for sustained growth.
- →The approach focuses on building science capability before capacity to ensure value delivery over the longer term.
Margin guidance
Category 3- →Sai Life Sciences projects mid-term revenue growth of **15% to 20%** over a 3-5 year period, emphasizing a longer-term view due to industry lumpiness.
- →Recently achieved **30% annualized growth** but maintains conservative guidance to manage expectations.
- →EBITDA margin guidance remains stable at **28% to 30%**.
- →Continued growth expected from integrated CRDMO model, expansion in peptide modalities, and new formulation capabilities.
- →Q2 FY27 and H2 FY27 expected to be stronger due to new capacity coming online.
- →Investments and capex are carefully planned with internal hurdle rates, balancing growth and disciplined capital allocation.
- →Expansion in dedicated FTE development contracts aims to deepen customer relationships and pipeline visibility, supporting sustained earnings growth.
- →Growth in CRO business (26% YoY in Q1 FY27) complements CDMO growth (~6% YoY), supporting overall performance.
3 more insights locked — sign up free to unlock
Fundraise plans
- →The transcript does not mention any current or planned fundraising through debt or equity.
- →The company emphasizes maintaining a healthy balance sheet and financial flexibility to invest in growth opportunities.
- →Management states they will balance investments with disciplined capital allocation and returns.
- →No explicit details on raising capital via debt or equity are provided for the near future.
Order book
- →Sai Life Sciences Limited has a healthy order book supported by a growing base of large pharmaceutical customers.
- →Over 90% of revenue in FY25 and FY26 came from returning customers, reflecting strong repeat orders.
- →The company secured six late-phase molecules to its pipeline in the past 15 months, five of which came through large pharma clients with ongoing FTE (Full-Time Equivalent) engagements.
- →Dedicated FTE development contracts are expected to augment the pipeline of late-phase and commercial molecules.
- →One large pharma collaboration has expanded into a sizable dedicated FTE contract, covering the complete product lifecycle from discovery to commercial manufacturing.
- →The discovery capacity expansion facility came on stream in Q1 and is already sold out, indicating strong demand.
- →CDMO capacity expansion (two production blocks totaling 450 KL) is on track to come on stream by H2 FY27 to meet order commitments.
- →Overall, the order pipeline is robust with continued conversion of pilot collaborations into long-term high-volume partnerships.
Capex plans
Yes- →Sai Life Sciences plans a capex of INR1,100 to INR1,300 crores for FY27; no guidance provided for FY28 yet.
- →A significant greenfield peptide manufacturing facility near Hyderabad is planned, expected operational by 2028.
- →Investment in building pilot scale conjugation facilities for ADCs is underway, spanning discovery and development stages.
- →New capacity is being developed for early to mid-stage deliveries at a new greenfield manufacturing site.
- →Formulation capabilities are being added, with the facility expected operational within six months, driven by customer interest.
- →Expansion includes two production blocks (225 KL each) in Bidar, totaling 450 KL, with the first block on track for H2 FY27.
- →Investments include flow chemistry capabilities and continuous downstream operations to handle complex molecules.
- →Capex decisions are evaluated against internal hurdle rates and can be deferred if business circumstances change.
How does Sai Life rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Sai Life
Rev 3Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
How does Sai Life rank in Pharmaceuticals & Biotechnology?
Compare Sai Life against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.